Payload Information
General Information of This Payload
| Payload ID | PAY0HANQZ |
|||||
|---|---|---|---|---|---|---|
| Name | Camptothecin analogue ED04 |
|||||
| Synonyms |
Camptothecin analogue ED04
Click to Show/Hide
|
|||||
| Target(s) | DNA topoisomerase 1 (TOP1) | |||||
| Structure |
|
|||||
| Formula | C28H29FN4O6 |
|||||
| Isosmiles | CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](NC(=O)[C@H](C)OCN)CC3 |
|||||
| InChI |
InChI=1S/C28H29FN4O6/c1-4-28(37)17-7-21-24-15(9-33(21)26(35)16(17)10-38-27(28)36)23-19(32-25(34)13(3)39-11-30)6-5-14-12(2)18(29)8-20(31-24)22(14)23/h7-8,13,19,37H,4-6,9-11,30H2,1-3H3,(H,32,34)/t13-,19-,28-/m0/s1
|
|||||
| InChIKey |
AWGWTUBRWCBFRS-ULMCSZMWSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
536.56 |
Polar area |
145.77 |
||
Complexity |
536.2071129 |
xlogp Value |
1.95192 |
|||
Heavy Count |
39 |
Rot Bonds |
5 |
|||
Hbond acc |
9 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BL-B01D1 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
61.80% (NSCLC EGFR mutation)
40.50% (NSCLC EGFR wildtype) 14.30% (SCLC) 45.80% (NPC) 7.70% (HNSCC) |
|||
| Patients Enrolled |
Patients with locally advanced or metastatic solid tumors.
|
||||
| Administration Dosage |
BL-B01D1 was administered intravenously at doses of 2.50, 3.00 mg/kg D1D8 Q3W and 4.50, 5.00, 6.00 mg/kg D1 Q3W.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05194982 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic solid tumor.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05785039 | Phase Status | Phase 2 | ||
| Clinical Description |
Phase 2a/2b clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [5] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05470348 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [6] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05393427 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic urological tumors and other solid tumors.
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [7] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05262491 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor.
|
||||
BL-M07D1 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05631964 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and initial efficacy of BL-M07D1 for injection in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05461768 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M07D1 injection in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.
|
||||
BL-M02D1 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [8] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05385692 | Phase Status | Phase 1 | ||
| Clinical Description |
Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic gastrointestinal tumors or other solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [9] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05339685 | Phase Status | Phase 1 | ||
| Clinical Description |
Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors.
|
||||
References